BioCentury
ARTICLE | Clinical News

Tideglusib: Phase II started

August 22, 2016 7:00 AM UTC

AMO began a single-blind, placebo-controlled, U.K. Phase II trial to evaluate 400 and 1,000 mg oral tideglusib for 14 weeks in up to 16 patients ages 12-45. AMO licensed rights to tideglusib from Nosc...